mTOR inhibitors in advanced renal cell carcinomas: from biology to clinical practice.
To date, oral everolimus is indicated for the treatment of patients with advanced renal cell carcinoma, whose disease has progressed on or after treatment with vascular endothelial growth factor-targeted therapy, and intravenous temsirolimus for the first-line treatment of patients with poor prognosis metastatic renal cell carcinoma. However, some factors could guide the treatment choice aiming to individualize a treatment plan. Besides the crucial issue of treatment efficacy, other factors are to be considered such as disease status, histological subtype, extent of the disease, patient-specific factors, and agent-specific factors. All of these considerations have to stay in the frame of guideline recommendations which represent evidence-based medicine. The purpose of this article is to summarize the main pharmacological and pharmacokinetic characteristics of mTOR inhibitors, and to define targeted populations according to prognostic indexes.
['Barthélémy|Philippe|P|', 'Hoch|Benjamin|B|', 'Chevreau|Christine|C|', 'Joly|Florence|F|', 'Laguerre|Brigitte|B|', 'Lokiec|François|F|', 'Duclos|Brigitte|B|']
D000970:Antineoplastic Agents D002292:Carcinoma, Renal Cell D019008:Drug Resistance, Neoplasm D006801:Humans D007680:Kidney Neoplasms D058990:Molecular Targeted Therapy D047428:Protein Kinase Inhibitors D015398:Signal Transduction D058570:TOR Serine-Threonine Kinases D016896:Treatment Outcome
mTOR inhibitors Everolimus Temsirolimus Kidney cancer